Routinely Collected Clinical Data and Evaluation of Antimicrobial Target Attainment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

323 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-03-19

Study Completion Date

2027-03-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary aim of the study is to determine the proportion of individuals receiving beta-lactam antibiotics at Imperial College Healthcare NHS Trust in whom drug concentration targets are achieved.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Detection of Anaerobes in Different Clinicalsamples

NCT03266341

Anaerobic Bacterial Infection

UNKNOWN

Pharmacokinetics of Small Spectrum Beta-lactam Antibiotics (Amoxicillin/Clavulanic Acid and Cefuroxime) in Patients on Intensive Care Units

NCT01581047

Infection

COMPLETED

Feasibility Studies to Inform Novel Proposals to Avert Community-Based Antimicrobial Resistance Spread

NCT02666274

Gram-Negative Bacterial Infections

UNKNOWN

ADAPT-AST (Adaptive Antimicrobial Susceptibility Testing)

NCT06297837

Urinary Tract Infections

ACTIVE_NOT_RECRUITING

Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome

NCT05302531

Short Bowel Syndrome Infection, Bacterial

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To address the challenge of antimicrobial resistance (AMR) it is imperative that the current finite pool of antimicrobial agents is optimised, to maximise therapeutic success, limit the risk of drug toxicity, whilst minimising emergence of resistance.

Outside of the critical care setting it is not known how many patients are receiving optimal drug concentrations for the treatment of infection.

This study aims to assess whether antimicrobial targets are being achieved in these individuals and explore how clinical co-variates and outcomes may relate to this. Furthermore, it aims to identify priority groups and/or drugs where there are gaps in dose optimisation research and develop hypotheses which can be tested in observational studies.

Eligible participants will be enrolled and observed during their management of infection at Imperial College NHS Trust. After providing informed consent their clinical data will be collected from electronic healthcare records and they will provide samples that will undergo drug concentration analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infections, Bacterial Pharmacokinetics Drug Monitoring Drug-Related Side Effects and Adverse Reactions

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

18 years of age or above.

* Under follow-up for management of infection at Imperial College NHS Trust
* Received a beta-lactam antibiotic within the last 48 hours (or are planned to start imminently).
* Provides informed written consent see below, or lacks capacity to provide consent because of one of the following conditions (and declaration provided by personal consultee):
* Delirium which may be caused or exacerbated by having an infection.
* Suspected/confirmed central nervous system infection.
* Critical illness requiring sedation and/or intubation and ventilation which is caused by or exacerbated by having an infection.

Exclusion Criteria

* Less than 18 years of age

* Severe anaemia (Hb \< 70g/l)
* Platelets \< 50x10\^9/l, INR \>1.5 or other known blood clotting impairment
* Patient with terminal diagnosis receiving palliative care input who may experience distress if approached for this study.
* Enrolled in a clinical trial which stipulates exclusion from other studies including observational studies.
* Patients with restricted liberty, prisoners or under legal protection.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No